Search research articles
Contact Us
Filters
Showing results (1-10 of 36) with videos related to
Page
of 4
Sort By:
Cancer Cell
|
October 26, 2002
Cancer therapeutics in yeast
Mary Ann Bjornsti
F1000Research
|
October 12, 2019
Topoisomerases and cancer chemotherapy: recent advances and unanswered questions
Mary-Ann Bjornsti, Scott H Kaufmann
Cancer Cell
|
June 15, 2004
Lost in translation: dysregulation of cap-dependent translation and cancer
Mary-Ann Bjornsti, Peter J Houghton
Expert Opinion on Therapeutic Targets
|
August 21, 2025
Rhabdomyosarcoma: development of molecular therapeutics under the microscope
Peter J Houghton, Mary-Ann Bjornsti
The Journal of Biological Chemistry
|
December 7, 2007
Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin
Marié van der Merwe, Mary-Ann Bjornsti
Cancer Biology & Therapy
|
July 25, 2003
Rapamycins: mechanism of action and cellular resistance
Shile Huang, Mary-Ann Bjornsti, Peter J Houghton
Cancer Chemotherapy and Pharmacology
|
May 22, 2017
DNA topoisomerase-targeting chemotherapeutics: what's new?
Selma M Cuya, Mary-Ann Bjornsti, Robert C A M van Waardenburg
The Journal of Biological Chemistry
|
February 6, 2007
Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality
Carmen Losasso, Erica Cretaio, Komaraiah Palle, et al.
Cell
|
August 21, 2010
Cellular strategies for regulating DNA supercoiling: a single-molecule perspective
Daniel A Koster, Aurélien Crut, Stewart Shuman, et al.
DNA Repair
|
May 23, 2006
Trapping of DNA topoisomerase I on nick-containing DNA in cell free extracts of Saccharomyces cerevisiae
Natalia Lebedeva, Patricia Auffret Vander Kemp, Mary-Ann Bjornsti, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 36) with videos related to
Sort By:
Page
of 4
Cancer Cell
|
October 26, 2002
Cancer therapeutics in yeast
Mary Ann Bjornsti
F1000Research
|
October 12, 2019
Topoisomerases and cancer chemotherapy: recent advances and unanswered questions
Mary-Ann Bjornsti, Scott H Kaufmann
Cancer Cell
|
June 15, 2004
Lost in translation: dysregulation of cap-dependent translation and cancer
Mary-Ann Bjornsti, Peter J Houghton
Expert Opinion on Therapeutic Targets
|
August 21, 2025
Rhabdomyosarcoma: development of molecular therapeutics under the microscope
Peter J Houghton, Mary-Ann Bjornsti
The Journal of Biological Chemistry
|
December 7, 2007
Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin
Marié van der Merwe, Mary-Ann Bjornsti
Cancer Biology & Therapy
|
July 25, 2003
Rapamycins: mechanism of action and cellular resistance
Shile Huang, Mary-Ann Bjornsti, Peter J Houghton
Cancer Chemotherapy and Pharmacology
|
May 22, 2017
DNA topoisomerase-targeting chemotherapeutics: what's new?
Selma M Cuya, Mary-Ann Bjornsti, Robert C A M van Waardenburg
The Journal of Biological Chemistry
|
February 6, 2007
Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality
Carmen Losasso, Erica Cretaio, Komaraiah Palle, et al.
Cell
|
August 21, 2010
Cellular strategies for regulating DNA supercoiling: a single-molecule perspective
Daniel A Koster, Aurélien Crut, Stewart Shuman, et al.
DNA Repair
|
May 23, 2006
Trapping of DNA topoisomerase I on nick-containing DNA in cell free extracts of Saccharomyces cerevisiae
Natalia Lebedeva, Patricia Auffret Vander Kemp, Mary-Ann Bjornsti, et al.
Page
of 4